IDEXX Laboratories (IDXX) Q4 2025 Earnings
Q4 GAAP diluted EPS includes $0.09 per share positive impact from currency changes and $0.07 per share in tax benefits from share-based compensation; company-reported non-GAAP comparable EPS was $2.92.
How Did IDXX Stock React to Q4 2025 Earnings?
Did IDXX Beat Earnings? Q4 2025 Results
Yes. IDEXX Laboratories reported Q4 2025 earnings of $3.08 a share on Feb 2, 2026, beating the $2.94 consensus estimate by 4.8%. Revenue was $1.1B against a $1.1B estimate.
IDEXX Laboratories closed its fourth quarter of fiscal 2025 with a broad-based beat, posting GAAP diluted EPS of $3.08 against a consensus estimate of $2.94, a 4.85% beat that extended the company's winning streak to five consecutive quarters of topping analyst expectations. Revenue of $1.09 billion grew 14.3% year over year, beating the $1.07 billion consensus by 1.73%, driven most visibly by a record quarter for instrument placements, including over 1,900 inVue Dx units and nearly 1,400 new and competitive Catalyst analyzers. The quarter's GAAP EPS included a $0.09 per share benefit from currency movements and $0.07 per share in share-based compensation tax benefits. Companion Animal Group diagnostics were the engine of growth, with CAG recurring revenue rising 12% on higher testing utilization, new reference lab customers and net price gains. Looking ahead, management guided 2026 revenue of $4.63 billion to $4.72 billion and EPS of $14.29 to $14.80, even as some analysts trimmed price targets on modest caution around pet visit trends that IDEXX expects to offset through pricing discipline and continued installed base expansion.
- CAG Diagnostics recurring revenue up 12% reported and 10% organic in Q4
- International CAG Diagnostics recurring revenue up 17% reported and 12% organic; U.S. up 9%
- Increased U.S. diagnostic frequency, including early benefits from an aging pet population
- Record quarterly instrument placements: over 1,900 IDEXX inVue Dx and nearly 1,400 new and competitive Catalyst placements
- Global premium instrument installed base up 12% year over year
- Net customer gains and net price realization
- Reference lab productivity initiatives supporting a 50 bps gross margin expansion to 60.3%
- Operating margin of 28.9%, up 150 bps reported
- Cloud-native software installed base expansion
- Q4 EPS helped by $0.09 from currency and $0.07 from share-based compensation tax benefits
“IDEXX delivered a strong finish to 2025, supported by consistently high levels of execution by IDEXX teams around the world.”
IDEXX Laboratories CEO, on the earnings call
What Was IDEXX Laboratories's Outlook in Q4 2025?
For 2026, IDEXX guides revenue of $4,632 million–$4,720 million. That represents growth of 7.6%–9.6% reported and 7.0%–9.0% organic. CAG Diagnostics recurring revenue is expected to grow 8.6%–10.6% reported and 8.0%–10.0% organic. This includes an estimated 4% benefit from net price improvement. Other 2026 targets: - **EPS:** $14.29–$14.80, up 9%–13% reported and 10%–14% comparable. - **Operating margin:** 32.0%–32.5%, an expansion of 40–90 bps reported and 30–80 bps comparable. - **Net interest expense:** about $34 million. - **Effective tax rate:** about 21.3%. - **Share-based compensation:** tax benefit of about $15 million, worth about $0.19 of EPS. - **Average shares outstanding:** 1%–2% reduction. - **Cash flow:** operating cash flow of 105%–115% of net income and free cash flow of 85%–95% of net income. - **Capital expenditures:** about $180 million. Currency is expected to add about 0.6% to revenue growth, about 30 bps to operating margin and about $0.22 to EPS.
IDXX YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $1.1B | $954.3M | +14.3% |
| Gross Profit | $658.1M | $570.6M | +15.3% |
| Operating Income | $315.6M | $261.7M | +20.6% |
| Net Income | $248.2M | $216.2M | +14.8% |
IDXX Revenue by Segment
IDXX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.